Integra LifeSciences (IART) Tops Q4 EPS by 3c ; Offers Guidance

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.83, $0.03 better than the analyst estimate of $0.80. Revenue for the quarter came in at $434.9 million versus the consensus estimate of $429.63 million.

GUIDANCE:

Integra LifeSciences sees Q1 2026 EPS of $0.37-$0.45, versus the consensus of $0.48. Integra LifeSciences sees Q1 2026 revenue of $375-390 million, versus the consensus of $392.1 million.

Integra LifeSciences sees FY2026 EPS of $2.30-$2.40, versus the consensus of $2.35. Integra LifeSciences sees FY2026 revenue of $1.66-1.7 billion, versus the consensus of $1.67 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Texas Capital Securities Reiterates Buy Rating on Texas Pacific Land Trust (TPL)
• SpaceX Draws $89 Billion Peak Demand For Debut High-grade Bond - Bloomberg